Immune Evasion and Immunotherapeutic Advances in Classical Hodgkin Lymphoma
DOI:
https://doi.org/10.58445/rars.3812Keywords:
Classical Hodgkin lymphoma, Hodgkin Reed–Sternberg cells, ImmunotherapyAbstract
Classical Hodgkin lymphoma (CHL) is a cancer of the lymphatic system characterized by Hodgkin Reed–Sternberg cells derived from B lymphocytes. While most patients respond well to chemotherapy and radiotherapy, some experience relapse or resistance, creating a need for new treatment approaches. This review examines how CHL evades immune detection through mechanisms such as reduced antigen presentation and increased expression of immune checkpoint proteins like PD-L1. It also discusses current immunotherapies, including checkpoint inhibitors and antibody-drug conjugates, as well as emerging treatments such as CAR T-cell therapy. Recent clinical research highlights how these advances are improving outcomes for patients with relapsed or refractory disease. Overall, immunotherapy has significantly improved survival in CHL and continues to offer promising potential for more durable remissions.
References
Ansell S. M. (2015). Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clinic proceedings, 90(11), 1574–1583. https://doi.org/10.1016/j.mayocp.2015.07.005
Chen, R., & Zinzani, P. L. (2023). Immunotherapy in classical Hodgkin lymphoma: Current status and future directions. Blood Reviews, 58, 100991. https://doi.org/10.1016/j.blre.2023.100991
Küppers, R. (2019). The biology of Hodgkin’s lymphoma. Nature Reviews Cancer, 19(1), 45–57. https://doi.org/10.1038/s41568-018-0105-7
Meier, J. A., Savoldo, B., & Grover, N. S. (2022). The emerging role of CAR T cell therapy in relapsed/refractory Hodgkin lymphoma. Journal of Personalized Medicine, 12(2), 197. https://doi.org/10.3390/jpm12020197
U.S. National Library of Medicine. (2023). NCT04268706: Phase II trial of autologous CD30 CAR T-cell therapy in relapsed/refractory classical Hodgkin lymphoma. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04268706
U.S. National Library of Medicine. (2023). NCT04134325: PD-1 blockade in relapsed CHL following CAR T-cell therapy. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04134325
Downloads
Posted
Categories
License
Copyright (c) 2026 Research Archive of Rising Scholars
This work is licensed under a Creative Commons Attribution 4.0 International License.
